OC
EDVA

Oppenheimer & Co’s Endovia Health Sciences, Inc. EDVA Stock Holding History

Oppenheimer & Co’s Portfolio EDVA Stock Details EDVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-146
Closed -$47K – 1560
2021
Q3 		$47K Buy
+146
New +$66K ﹤0.01% 1470

Other funds holding EDVA

PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Oppenheimer & Co's EDVA Position: Q4 2021 in Review

Oppenheimer & Co sold out of Endovia Health Sciences, Inc. (EDVA) in Q4 2021, closing a stake of 146 shares — an estimated $47K sold.

Oppenheimer & Co first reported a position in EDVA in Q3 2021 and held it in 1 quarter. The position peaked at $47K in Q3 2021. 14 funds tracked by Wall St. Rank hold EDVA as of Q4 2021.

  • Oppenheimer & Co reported no remaining Endovia Health Sciences, Inc. position as of Q4 2021 after selling out during the quarter.
  • Oppenheimer & Co sold 146 Endovia Health Sciences, Inc. shares in Q4 2021, an estimated $47K.
  • Oppenheimer & Co first reported a position in Endovia Health Sciences, Inc. in Q3 2021 and held it in 1 quarter.
  • Oppenheimer & Co's Endovia Health Sciences, Inc. position peaked at $47K in Q3 2021.
  • 14 funds tracked by Wall St. Rank held Endovia Health Sciences, Inc. as of Q4 2021.

Based on Oppenheimer & Co's 13F filing for Q4 2021, filed 2 Feb 2022.